Cingulate Stock Today
| CING Stock | USD 7.70 1.21 18.64% |
PerformanceSolid
| Odds Of DistressModerate
|
Cingulate is trading at 7.70 as of the 7th of February 2026. This is a 18.64 percent increase since the beginning of the trading day. The stock's lowest day price was 6.53. Cingulate has over 58 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat solid returns during the last 90 days. The performance scores are derived for the period starting the 9th of November 2025 and ending today, the 7th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of December 2021 | Category Healthcare | Classification Health Care |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 7.45 M outstanding shares of which 270.81 K shares are currently shorted by private and institutional investors with about 1.39 trading days to cover. More on Cingulate
Moving together with Cingulate Stock
Moving against Cingulate Stock
Cingulate Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Principal CEO | PharmD PharmD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCingulate utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Cingulate's leverage profile, showing how much of Cingulate's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cingulate (CING) is traded on NASDAQ Exchange in USA and employs 13 people. Cingulate is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.34 M. Cingulate conducts business under Biotechnology sector and is part of Health Care industry. The entity has 7.45 M outstanding shares of which 270.81 K shares are currently shorted by private and institutional investors with about 1.39 trading days to cover.
Cingulate currently holds about 8.2 M in cash with (18.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73.
Check Cingulate Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cingulate is $57.34 Million. Almost 93.23 percent of Cingulate outstanding shares are held by general public with 1.38 (percent) owned by insiders and only 5.39 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cingulate Ownership Details
Cingulate Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sbi Securities Co Ltd | 2025-06-30 | 251 | |
| Advisor Group Holdings, Inc. | 2025-06-30 | 42.0 | |
| Commonwealth Equity Services Inc | 2025-06-30 | 120.5 K | |
| Vanguard Group Inc | 2025-06-30 | 35.4 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 33.2 K | |
| Geode Capital Management, Llc | 2025-06-30 | 32.2 K | |
| Virtu Financial Llc | 2025-06-30 | 13.4 K | |
| Ubs Group Ag | 2025-06-30 | 12.6 K | |
| Lpl Financial Corp | 2025-06-30 | 12.2 K | |
| Xtx Topco Ltd | 2025-06-30 | 10.9 K | |
| Bank Of America Corp | 2025-06-30 | 7.5 K |
Cingulate Historical Income Statement
Cingulate Stock Against Markets
Cingulate Corporate Management
| Craig Esq | Gen VP | Profile | |
| Thomas Dalton | Head Relations | Profile | |
| Bryan Downey | Chief Officer | Profile | |
| Downey Wade | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Can Biotechnology industry sustain growth momentum? Does Cingulate have expansion opportunities? Factors like these will boost the valuation of Cingulate. Projected growth potential of Cingulate fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cingulate demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Cingulate requires distinguishing between market price and book value, where the latter reflects Cingulate's accounting equity. The concept of intrinsic value - what Cingulate's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cingulate's price substantially above or below its fundamental value.
It's important to distinguish between Cingulate's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cingulate should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cingulate's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.